Search results for "Adjuvant"

showing 10 items of 733 documents

Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

2018

Background Nanoparticle (NP)–based vaccines are attractive immunotherapy tools because of their capability to codeliver antigen and adjuvant to antigen-presenting cells. Their cellular distribution and serum protein interaction ("protein corona") after systemic administration and their effect on the functional properties of NPs is poorly understood. Objectives We analyzed the relevance of the protein corona on cell type–selective uptake of dextran-coated NPs and determined the outcome of vaccination with NPs that codeliver antigen and adjuvant in disease models of allergy. Methods The role of protein corona constituents for cellular binding/uptake of dextran-coated ferrous nanoparticles (DE…

0301 basic medicineendocrine systemOvalbuminCpG OligodeoxynucleotideT-Lymphocytesmedicine.medical_treatmentImmunologyMice Transgenic02 engineering and technologyComplement factor IComplement receptor03 medical and health sciencesImmune systemAntigenLectinsHypersensitivitymedicineAnimalsImmunology and AllergyFerrous CompoundsAntigensAnaphylaxisB-LymphocytesDrug CarriersMice Inbred BALB CVaccinesChemistryDextransImmunotherapyrespiratory system021001 nanoscience & nanotechnologyComplement systemMice Inbred C57BL030104 developmental biologyOligodeoxyribonucleotidesImmunologyNanoparticlesFemaleProtein Corona0210 nano-technologyAdjuvantJournal of Allergy and Clinical Immunology
researchProduct

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

2018

Nanocarriers (NC) are very promising tools for cancer immunotherapy. Whereas conventional vaccines are based on the administration of an antigen and an adjuvant in an independent fashion, nanovaccines can facilitate cell-specific co-delivery of antigen and adjuvant. Furthermore, nanovaccines can be decorated on their surface with molecules that facilitate target-specific antigen delivery to certain antigen-presenting cell types or tumor cells. However, the target cell-specific uptake of nanovaccines is highly dependent on the modifications of the nanocarrier itself. One of these is the formation of a protein corona around NC after in vivo administration, which may potently affect cell-speci…

0301 basic medicinelcsh:Immunologic diseases. AllergyMini Reviewmedicine.medical_treatmentImmunologyCellcell-specific targetingProtein Corona02 engineering and technology03 medical and health sciencesprotein coronaAntigenCancer immunotherapyIn vivoNeoplasmsmedicineHumansImmunology and AllergyReceptors ImmunologicnanocarriersChemistryImmunotherapy021001 nanoscience & nanotechnologyBody FluidsTreatment Outcome030104 developmental biologymedicine.anatomical_structureCancer researchNanoparticlesimmunotherapyNanocarriers0210 nano-technologylcsh:RC581-607Adjuvantcancer vaccinesProtein BindingFrontiers in Immunology
researchProduct

Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.

2020

Objective. To determine the factors related with diverting ileostomy performance after colorectal resection and anastomosis, in advanced ovarian cancer cytoreductive surgery. Methods. We have previously demonstrated the risk factors associated with anastomotic leak after colorectal anastomosis: Advanced age at surgery, low serum albumin level, additional bowel resections, manual anastomosis and distance of the anastomosis from the anal verge. However, use of diverting ileostomy is strongly variable and depends on individual surgeon preferences and training. Eight hospitals participated in this retrospective study. Data of 695 patients operated for ovarian cancer with primary colorectal anas…

0301 basic medicinemedicine.medical_specialtyBevacizumabAnastomotic LeakGynecologic oncologyAnastomosisStomaCohort Studies03 medical and health sciences0302 clinical medicineDiverting ileostomyOvarian cancerAnastomotic leakMedicineHumansPractice Patterns Physicians'AgedNeoplasm StagingRetrospective StudiesOvarian Neoplasmsbusiness.industryIleostomyAnastomosis SurgicalObstetrics and GynecologyRetrospective cohort studyPerioperativeCytoreduction Surgical Proceduresmedicine.diseaseNeoadjuvant TherapySurgeryBevacizumab030104 developmental biologyRisk factorsOncology030220 oncology & carcinogenesisCohortFemaleRisk factorbusinessOvarian cancerColorectal Neoplasmsmedicine.drugGynecologic oncology
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis

2021

AbstractSevere acute respiratory syndrome coronavirus 2 has spread rapidly throughout the world, becoming an overwhelming global health emergency. The array of injuries caused by this virus is broad and not limited to the respiratory system, but encompassing also extensive endothelial and systemic tissue damage. Since statins effectively improve endothelial function, these drugs may have beneficial effects in patients with coronavirus disease 2019 (COVID-19). Therefore, this investigation aimed to provide an updated overview on the interplay between statins and COVID-19, with particular focus on their potentially protective role against progression toward severe or critical illness and deat…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_class030204 cardiovascular system & hematologyStatins COVID-19 Meta-analysislaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyGlobal healthHumansSARS-CoV-2business.industryStatinsCOVID-19HematologyOdds ratioUnited StatesConfidence intervalCOVID-19 Drug TreatmentReview articleEuropeHospitalizationMeta-analysis030104 developmental biologyMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

2019

Background Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective, would be extremely beneficial. A pooled analysis of data for 12 834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the International Duration Evaluation of Adjuvant chemotherapy study, was carried out and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice, ESMO decided to s…

0301 basic medicinemedicine.medical_specialtyTime FactorsColorectal cancerRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansMulticenter Studies as TopicColectomyNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryCAPOX RegimenHematologyCongresses as Topicmedicine.diseaseChemotherapy regimenOxaliplatinClinical trialOxaliplatinRegimen030104 developmental biologyOncologyClinical Trials Phase III as TopicChemotherapy Adjuvant030220 oncology & carcinogenesisData Interpretation StatisticalColonic NeoplasmsPractice Guidelines as TopicQuality of LifeNeurotoxicity Syndromesbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19☆

2020

Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-C…

0301 basic medicinemedicine.medical_specialtyVitamina Cmedicine.drug_classLung injurymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineOzoneIntensive caremedicineAdjuvant therapyVitamin CIntensive care medicineOzonoCoronavirusbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicineGeneral MedicineAscorbic acidmedicine.diseaseClinical trialPneumonia030104 developmental biologyAntiviral drugbusinessRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

2019

A poor preoperative functional capacity increases the perioperative risk. Therefore, a web-based exercise approach has been initiated for a careful supervision and individual support of patients during their perioperative cancer therapy. Here, we present the data of a 57-year-old patient, scheduled for esophagectomy. Beside a five-week neoadjuvant chemoradiotherapy (CRT), the patient performed 10 weeks of a web-based prehabilitation exercise training (preconditioning) and continued the exercise program for 14 weeks after surgery. The patient performed 42 of 44 recommended training sessions in the preconditioning period in his home environment. This corresponds to a mean of 131 (±38) min of …

0301 basic medicinemedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPrehabilitationPerioperativeEsophageal cancermedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyEsophagectomy030220 oncology & carcinogenesismedicineCarcinomaPhysical therapyExercise intensityWeb applicationbusinessNeoadjuvant therapyCase Reports in Oncology
researchProduct

A thoracic vertebral localization of a metastasized cutaneous Merkel cell carcinoma: Case report and review of literature

2017

Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin tumor, which may be related to sun exposure. It can metastasize to lungs, liver and bone, leading to severe morbidity and mortality. Vertebral metastases from MCC are rare. The authors report the tenth case in the literature, a 59-year-old patient with MCC, which was primarily localized in the scalp, and later provoked distant metastasis to the thoracic spinal column. Case Description: A 59-year-old woman was admitted at our Unit of Neurosurgery with a 4-month history of progressive and severe dorsal back pain, without neurological signs. The patient had been surgically treated for a recidivated MCC in the occipital regio…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment03 medical and health sciencesMerkel cell carcinomamedicineAdjuvant therapymedicine.diagnostic_testbusiness.industryMerkel cell carcinomaSettore MED/27 - NeurochirurgiaMagnetic resonance imagingmedicine.diseaseSpinal columnSurgeryRadiation therapySpine: Case ReportDissection030104 developmental biologymedicine.anatomical_structurespinal metastasisScalpSurgeryNeurology (clinical)Neurosurgerybusinessradiofrequency thermoablationSurgical Neurology International
researchProduct

Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.

2017

Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, “self-antigens”, that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid:cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer…

0301 basic medicinemedicine.medical_treatmentchemical and pharmacologic phenomenaBiochemistryCancer Vaccines03 medical and health sciencesMice0302 clinical medicineImmune systemCancer immunotherapyAdjuvants ImmunologicDrug DiscoverymedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsMUC1PharmacologyVaccines SyntheticbiologyChemistryImmunogenicityOrganic ChemistryMucin-1GlycopeptidesDendritic CellsVirologyGlycopeptideToll-Like Receptor 3030104 developmental biologyPoly I-C030220 oncology & carcinogenesisTLR3biology.proteinMolecular MedicineAntibodyAdjuvantChemMedChem
researchProduct